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Ubiquitin-Independent 
Proteasomal Degradation 
Mediated by Antizyme
Noriyuki Murai
Abstract
Most of the proteins in eukaryotic cells are degraded by the proteasome in an 
ubiquitin-dependent manner. However, ubiquitin-independent protein degrada-
tion pathway by the 26S proteasome exists in the cells. Ornithine decarboxylase 
(ODC) is a well-known protein that is degraded by the 26S proteasome without 
ubiquitination. Degradation of ODC requires the protein, “antizyme (AZ),” that 
is induced by polyamine and binds to the ODC monomer to inhibit ODC activity 
and target it to the 26S proteasome for proteolytic degradation. Namely, AZ con-
tributes the feedback regulation of intracellular polyamine level. ODC has been 
considered to be the only protein that AZ binds and accelerates its degradation. 
However, recently AZ-mediated proteasomal protein degradation will gradually 
increase. Most recently, we found that one of the antizyme families, AZ2, acceler-
ates c-Myc degradation by the proteasome without ubiquitination. In this chapter, 
we introduce latest several ubiquitin-independent proteasomal degradation 
mediated by antizyme.
Keywords: antizyme, ubiquitin-independent degradation, ornithine decarboxylase, 
26S proteasome, polyamines, c-Myc
1. Introduction
In eukaryotic cells, intracellular protein degradation is mainly regulated by 
the ubiquitin-proteasome system, where abnormal and unwanted proteins are 
targeted by polyubiquitin, which is produced from monoubiquitin by ubiquitin-
activating enzyme (E1) and ubiquitin-conjugating enzyme (E2) [1]. The proteins 
that conjugated polyubiquitin by ubiquitin ligase (E3) are finally targeted to the 
26S proteasome [2]. However, there is accumulating evidence that ubiquitin-
independent proteasomal protein degradation pathway exists in the cells [3, 4]. 
Although ubiquitin-dependent proteasomal protein degradation is carried out 
normally by 26S proteasome, there are many reports that ubiquitin-independent 
proteasomal protein degradations are executed by the only 20S proteasome with-
out the energy of ATP hydrolysis [4]. Among others, some ubiquitin-independent 
degradation pathways are known to be carried out using not the 20S but the 26S 
proteasome with the energy of ATP hydrolysis. In this chapter, we introduce 
ubiquitin-independent proteasomal degradation pathway mediated by polyamine 
regulating protein, “antizyme.”
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2. What is antizyme?
Polyamines are highly charged bioactive substances presented ubiquitously in 
species from bacteria to human. Polyamines are necessary for cell growth and are 
involved in highly diversified cellular functions such as cell division, apoptosis, 
autophagy, oxidative stress, and ion channel activity. There are three major poly-
amines, putrescine, spermidine, and spermine, in the cells [5, 6]. Intracellular poly-
amine concentration is highly regulated by the protein “antizyme” [7–10] that is 
widely distributed from yeast to human [11]. Antizyme (AZ) is induced in response 
to the increased concentration of intracellular polyamines through the polyamine-
induced translational frameshifting mechanism [12]. AZ mRNA consists of two 
ORFs (ORF1 and ORF2). In the low polyamine concentration, translation of 
ORF1 is terminated at stop codon “UGA” of ORF1, and short product is produced 
(Figure 1). But in the increasing cellular polyamine concentration, reading frame 
Figure 1. 
Negative feedback regulation of cellular polyamine by antizyme. Three cis-acting elements, UGA stop codon, 
upstream stimulator, and pseudoknot structure, are known to be important for +1 frameshifting (bottom 
column). Putrescine, spermidine, and spermine are major polyamines in the mammalian cell. Putrescine 
synthesized from ornithine by ODC could be metabolized to spermidine and spermine in the cells. PAT is a 
polyamine transporter that uptakes polyamines from outside of the cells.
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shifts +1 direction at the end of ORF1 (Figure 1 bottom column). In this case, 
following ORF1, ORF2 is translated and full length active product “antizyme” is 
produced [12, 13]. The induced AZ protein binds to ornithine decarboxylase (ODC) 
monomer, a key enzyme in polyamine biosynthesis, and catalyzes the conversion 
from ornithine to putrescine and inhibits its activity. AZ-bound ODC is targeted 
to the 26S proteasome for degradation without ubiquitination (Figure 1) [14]. AZ 
also suppresses polyamine uptake by inhibiting membrane polyamine transporter 
(Figure 1) [15, 16]. Thus, AZ provides the negative feedback regulation of cellular 
polyamines. In addition, AZ is regulated by the protein, antizyme inhibitor (AZIN), 
that is homologous to ODC and can bind to AZ with higher affinity than ODC but 
lacking the enzymatic activity [17, 18].
In mammals, cells express three members of AZ protein family, AZ1–3 (Table 1) 
[19]. AZ1 and AZ2 are distributed ubiquitously in most of the tissues, whereas 
AZ3 is testis specific [20–22]. Both AZ1 and AZ2 bind to ODC and accelerate its 
Table 1. 
Characteristics of antizyme family.
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degradation in the cells [9, 23], but AZ3 has no activity for acceleration of ODC 
degradation [24]. The rate of ODC degradation by AZ1 is faster than that by AZ2 
[23, 25]. Polyamine (putrescine) concentration of AZ1 knockdown cells is markedly 
increased, compared to that of AZ2 knockdown and control cells [26]. Therefore, 
it is thought that AZ1 mainly regulates cellular polyamine concentration. On the 
other hand, although AZ2 is highly homologous to AZ1 [25], it is considered that 
AZ2 is not a backup of AZ1 because of some differences between each other. AZ2 
was found as one of the genes upregulated in neuronal cells by the drug that induces 
seizure [27]. Nucleic acid sequence of AZ2 is evolutionally conserved higher than 
that of AZ1 [11]. AZ2 is localized mainly in the nucleus [26] and is phosphorylated 
in the cells [28]. We will mention about AZ2 specific function with its interacting 
protein that we found very recently in this chapter.
3.  Antizyme-interacting proteins and ubiquitin-independent 
proteasomal degradation
3.1 Antizyme 1-interacting proteins
It had been considered that ODC is the only protein degraded through 
AZ-mediated ubiquitin-independent proteasomal degradation system. However, 
recently several AZ1-interacting proteins other than ODC have been reported 
(Table 2). Although it has already been reported that those proteins are degraded 
by the ubiquitin-proteasome pathway, AZ1 could also accelerate those degradation 
without ubiquitination (Tables 1 and 2, Figure 1). Smad1, which is involved in 
bone morphogenetic protein (BMP) signaling pathway [29, 30], is the first reported 
protein that interacts AZ1 other than ODC [31]. In this case, newly synthesized 
HsN3, which is β-subunit for 20S proteasome, forms ternary complex with AZ1 and 
smad1. This complex may bind to 20S proteasome, and next 19S complex is docked 
on 20S, and then smad1 is degraded by the 26S proteasome.
Newman et al. reported that AZ1 has the ability to accelerate the degradation of 
cyclin D1, one of the cell cycle regulatory protein families [32]. Cyclin D1 interacts 
with cyclin-dependent kinase (CDK), and accumulation of cyclin D1-CDK complex 
is important for cell cycle progression [33]. This protein is already known to be 
degraded by ubiquitin-proteasome pathway [34]. They demonstrated that AZ1 
induction by polyamine or overexpression of AZ1 accelerates cyclin D1 degradation, 
and knockdown of AZ1 suppresses it. Furthermore, in vitro experiment using puri-
fied cyclin D1, AZ1, and rabbit reticulocyte extracts as a source of 26S proteasome, 
AZ1 accelerated cyclin D1 degradation in a ATP-dependent manner. AZ1 could 
also degrade ubiquitin-deficient mutant of cyclin D1 in the cells [32]. In vitro size 
distribution analysis for binding between AZ1, cyclin D1, and ODC suggested that 
binding sites of AZ1 for cyclin D1 and ODC do not overlap each other, and cyclin 
D1 binds to the N-terminus of AZ1 and ODC binds at the C-terminus, respectively. 
Binding affinity of AZ1 to cyclin D1 is fourfold lower than that to ODC [35]. 
Although physiological significance is not clear, it showed that those three proteins 
form cyclin D1-AZ1-ODC ternary complex.
The oncogene Aurora A encodes a protein kinase that exerts essential roles in 
mitotic events and is important for induction of centrosome amplification [36]. 
Overexpression of Aurora A in many cancers induces aneuploidy, centrosome 
anomaly, poor prognosis, and invasiveness [37, 38]. Aurora A is ubiquitinated by 
the E3 ubiquitin (Ub) ligase, anaphase-promoting complex/cyclosome (APC/C) 
that is activated by both cell-division cycle protein 20 (Cdc20) and Cdh1, 
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substrate-recognition subunit of APC/C, and is degraded by the proteasome [39, 
40]. However, Lim and Gopalan demonstrated that AZ1 could accelerate Aurora 
A degradation with ubiquitin-independent manner, where Aurora A kinase-
interacting protein 1 (AURKAIP1), a negative regulator of Aurora A, enhances 
the binding of AZ1 to Aurora A and facilitates the recognition of Aurora A by the 
proteasome [41].
Table 2. 
The proteins degraded by antizyme-mediated ubiquitin-independent proteasomal pathway.
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Mps1 is protein kinase required for centrosome duplication in regulating the 
spindle assembly checkpoint [42, 43]. Accumulation of Mps1 at the centrosome 
causes aberrant centriole assembly [44, 45]. In fact in various tumor cells, centro-
somal Mps1 pool is increased, which causes abnormal centrosome duplication [44]. 
Thus degradation of Mps1 is important for proper pool of Mps1 at the centrosome. 
Although degradation of Mps1 is known to be mediated by the proteasome, amino 
acid residue 420–507 of the human Mps1 that is sufficient for its degradation does 
not contain APC/C recognition motifs, suggesting the commitment of Mps1 to 
ubiquitin-independent proteasomal degradation [45]. Kasbek et al. reported that 
AZ1 localizes to the centrosomes and binds to Mps1 to control the levels of centro-
somal Mps1 by accelerating the degradation of Mps1 [46]. Fluorescent microscopy 
analysis showed that centrosomal Mps1 level is dependent on AZ1 expression, 
overexpression of AZ1 decreases the centrosome Mps1 level, and conversely, AZ1 
knockdown by siRNA increases that. Furthermore, deletion of degradation signal 
of Mps1 abolished the regulation of centrosomal Mps1 level by AZ1. In addition, 
overexpressing AZIN in the cells to trap AZ1 and inhibit its function increased 
centrosomal Mps1 level. Thus the balance of AZ1 and Mps1 level in the centrosome 
is important for the centrosome duplication process.
P73 is a homolog of p53 and exists as two major forms, TAp73 or Delta-N (DN) 
p73. TAp73 is full-length form and exerts proapoptotic function, whereas DNp73, 
which is amino-terminal transactivation domain lacking the form of p73, exhibits 
dominant-negative inhibitor activity for both p73 and p53, resulting in antiapop-
totic properties [47]. Therefore, in the stress condition like DNA damage, reduction 
of DNp73 level is needed to execute apoptosis [48–50]. It is known that degradation 
of both TAp73 and DNp73 is mediated by E3-ubiquitin ligase Itch in a proteasome-
dependent manner in normal condition [51]. However, in Itch-decreased condition 
such as DNA damage by UV irradiation, stabilization of TAp73 was observed, but 
DNp73 was not [51]. Therefore, it was considered that the degradation of TAp73 
and DNp73 is regulated by different mechanisms. Dulloo et al. reported that 
reduction of DNp73 in the stress condition is due to the degradation of DNp73 by 
AZ1-mediated ubiquitin-independent proteasomal pathway [52]. They showed that 
degradation of DNp73 could be induced by genotoxic stresses such as UV irradia-
tion and doxorubicin treatment. Inhibition of ubiquitin-activating enzyme E1 by 
the inhibitor PYR41 could not block DNp73 degradation, indicating that it relies 
on ubiquitin-independent pathway. They demonstrated that polyamine induced 
AZ1 to bind to DNp73 for accelerating its degradation. Interestingly, AZ1-mediated 
DNp73 degradation is dependent on transcription factor c-Jun that is activated by 
stress signals. Overexpression and knocking down of AZ1 also showed that even 
in the presence of c-Jun, AZ1 is necessary for genotoxic stress to induce DNp73 
degradation. Although it is not clear how c-Jun operates AZ1 expression, c-Jun may 
act upstream of polyamine biosynthesis pathway.
Thus, several proteins degraded by AZ1-mediated proteasome pathway are 
found, but AZ2-interacting protein or AZ2-mediated proteasomal degradation 
other than ODC has not been reported. We recently found two AZ2-interacting 
proteins, and one of the two was the protein that accelerated its proteasomal degra-
dation by AZ2 without ubiquitination (see next section).
3.2 Antizyme 2-interacting proteins
As mentioned above, AZ2 also binds to ODC and accelerates its degradation in 
the cells [9]. However, we have considered that AZ2 has specific function other than 
AZ1 because of the differences such as nuclear localization [26, 28], highly gene 
conservation between species [20], and high expression in neuronal cells [53]. We 
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performed comprehensive analysis of AZ2-interacting protein using two-hybrid 
technique. Two AZ2-interacting proteins were identified. One is ATP citrate lyase 
(ACLY), which is the enzyme catalyzing acetyl-CoA production in cytosol [54] 
and related to lipid anabolism and acetylation of cellular components [55]. We 
found that ACLY binds not only to AZ2 but also to AZ1 by immunoprecipitation 
assay [56]. Degradation assay for ACLY was performed in expectation of ubiquitin-
independent proteasomal degradation. However, AZs have no ability to accelerate 
ACLY degradation. Surprisingly, AZ1 and AZ2 activate catalytic activity of ACLY 
[56]. The other is proto-oncogene c-Myc that is a transcription factor with a basic 
region/helix–loop–helix/leucine zipper domain and forms heterodimer with Max 
for DNA binding [57, 58]. c-Myc functions as a master regulator of a variety of 
cellular processes such as cell growth, differentiation, survival, and apoptosis [58]. 
In cell growth, c-Myc targets ODC gene [59] and promotes synthesis of polyamine 
that is important for stabilization of nucleic acids, transcription, translation, and +1 
frameshifting on AZ mRNA [6].
It is known that degradation of c-Myc is mediated by ubiquitin-proteasome path-
way, where c-Myc is phosphorylated at Thr-58 (pT58) and Ser-62 (pS62) by extra-
cellular signal-regulated kinase, ERK, and glycogen synthase kinase 3β, GSK-3β, 
respectively [60, 61]. After dephosphorylation at Ser-62 by protein phosphatase 2A, 
PP2A, pT58-c-Myc is ubiquitinated by E3-ubiquitin ligase Fbxw7 for proteasomal 
degradation [60, 62]. At first, AZ2-interacting protein identified by the compre-
hensive analysis mentioned above was not c-Myc but a protein that has basic region/
helix–loop–helix/leucine zipper domain and interacts with c-Myc (Murai et al., 
manuscript in preparation). However, in the process of analyzing the interaction 
with AZ2, we found that AZ2 interacts with c-Myc in the cells by immunoprecipita-
tion assay. Subcellular localization analysis of both proteins using fluorescent protein 
tags or antibody conjugated fluorescent probe revealed that AZ2 co-localized with 
Figure 2. 
AZ2-mediated c-MYC degradation in the nucleolus. Two distinct c-Myc degradation pathways exist in the cells. 
It is thought that AZ2 pathway functions under the stress condition (polyamine increased condition) such as 
glucose-free and hypoxia.
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c-Myc in the nucleus. Treatment of proteasome inhibitor MG132 changes the nuclear 
co-localization of both proteins to nucleolar co-localization [26]. Overexpression of 
AZ2 or addition of polyamine in the cells accelerated c-Myc degradation, and knock-
down of AZ2 with siRNA suppressed it. Furthermore, E1 inhibitor PYR-41 could not 
suppress AZ2-mediated proteasomal c-Myc degradation [26]. These results suggest 
that AZ2-mediated ubiquitin-independent nucleolar c-Myc degradation pathway 
other than ubiquitin-dependent one exists in the cells (Figure 2).
4. Conclusions
In this chapter, antizyme-mediated ubiquitin-independent proteasomal deg-
radation has been discussed. All the proteins mentioned above are already known 
as the proteins degraded by ubiquitin-proteasomal pathway. It is not clear how 
antizyme-mediated ubiquitin-independent degradation of these proteins is physio-
logically significant. Normally subcellular localization of ODC is mainly in the cyto-
plasm and at least not in the nucleolus even in the presence of MG132. In addition, 
ODC is necessary for cell growth, and the affinity of interaction between antizyme 
and ODC is high [63]; in such condition, ODC probably occupies almost all anti-
zymes in the cytosol, and antizymes hardly function for other antizyme-interacting 
proteins [64]. In this context, because subcellular localization of both AZ2 and its 
interacting protein c-Myc is in the nucleus or nucleolus, cytosolic protein ODC 
could not interact with AZ2 there. ODC is one of the c-Myc-targeting proteins, and 
AZ2 may function upstream of c-Myc especially under the stress condition such as 
glucose free and hypoxic condition [26]. Further studies are needed to elucidate the 
significance of antizyme-proteasome degradation pathway.
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